Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders.
Zahra Alirezaei,Mohammad Hossein Pourhanifeh,Sarina Borran,Majid Nejati,Hamed Mirzaei,Michael R. Hamblin +5 more
Reads0
Chats0
TLDR
The evidence for NfL being a reliable biomarker in the early detection and disease management in several CNS-related disorders is summarized and the correlation between MRI and N fL is highlighted and asked whether they can be combined.Abstract:
The search for diagnostic and prognostic biomarkers for neurodegenerative conditions is of high importance, since these disorders may present difficulties in differential diagnosis. Biomarkers with high sensitivity and specificity are required. Neurofilament light chain (NfL) is a unique biomarker related to axonal damage and neural cell death, which is elevated in a number of neurological disorders, and can be detected in cerebrospinal fluid (CSF), as well as blood, serum, or plasma samples. Although the NfL concentration in CSF is higher than that in blood, blood measurement may be easier in practice due to its lesser invasiveness, reproducibility, and convenience. Many studies have investigated NfL in both CSF and serum/plasma as a potential biomarker of neurodegenerative disorders. Neuroimaging biomarkers can also potentially improve detection of CNS-related disorders at an early stage. Magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) are sensitive techniques to visualize neuroaxonal loss. Therefore, investigating the combination of NfL levels with indices extracted from MRI and DTI scans could potentially improve diagnosis of CNS-related disorders. This review summarizes the evidence for NfL being a reliable biomarker in the early detection and disease management in several CNS-related disorders. Moreover, we highlight the correlation between MRI and NfL and ask whether they can be combined.read more
Citations
More filters
Journal ArticleDOI
Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
Frederic Sampedro,Rocío Pérez-González,Saul Martinez-Horta,Juan Marín-Lahoz,Javier Pagonabarraga,Jaime Kulisevsky +5 more
TL;DR: Serum NfL levels reflect cortical neurodegeneration from the very early stages of PD, and its brain structural correlates and its lack of relationship with dopaminergic depletion or amyloidosis suggests that N fL could track the underlying pathological process leading to PD dementia.
Journal ArticleDOI
Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS.
Alexandre Brodovitch,José Boucraut,Emilien Delmont,Amandine Parlanti,Aude-Marie Grapperon,Shahram Attarian,Annie Verschueren +6 more
TL;DR: In this article, the authors evaluated the prognosis and diagnostic potential of both Neurofilament-Light (Nf-L) and neuroinflammatory biomarkers in serum and CSF.
Journal ArticleDOI
Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update
TL;DR: The novel innovative therapeutic targets for PD therapy, including α-synuclein, autophagy, neurodegeneration, neuroinflammation, and others are addressed, and molecular biomarkers under active investigation are presented as potentially valuable tools for early PD diagnosis.
Journal ArticleDOI
Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug-resistant epilepsy.
Oumarou Ouédraogo,Rose-Marie Rébillard,Hélène Jamann,Victoria Hannah Mamane,Marie-Laure Clénet,Audrey Daigneault,Boaz Lahav,Timo Uphaus,Falk Steffen,Stefan Bittner,Frauke Zipp,Arline Bérubé,Samuel Lapalme-Remis,Patrick Cossette,Dang Khoa Nguyen,Nathalie Arbour,Mark R. Keezer,Catherine Larochelle +17 more
TL;DR: Investigation of differences in immune cell populations, cytokines, and neurodegenerative biomarkers in the peripheral blood of subjects with epilepsy versus healthy controls, and in DRE compared to well‐controlled epilepsy (WCE).
Journal ArticleDOI
The relationship between neurofilament light chain and cognition in neurological disorders: A scoping review.
TL;DR: The objective of this scoping review was to determine whether a consistent relationship between NfL and cognition exists in the context of variable degrees of neurodegeneration present across several neurological disorders.
References
More filters
Journal ArticleDOI
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
TL;DR: The pathological findings in 100 patients diagnosed prospectively by a group of consultant neurologists as having idiopathic Parkinson's disease are reported, and these observations call into question current concepts of Parkinson's Disease as a single distinct morbid entity.
Journal ArticleDOI
Mutation in the α-synuclein gene identified in families with Parkinson's disease
Mihael H. Polymeropoulos,Christian Lavedan,Elisabeth Leroy,Susan E. Ide,Anindya Dehejia,Amalia Dutra,Brian L. Pike,Holly Root,Jeffrey Rubenstein,Rebecca Boyer,Edward S. Stenroos,Settara C. Chandrasekharappa,Aglaia Athanassiadou,Theodore Papapetropoulos,William G. Johnson,Alice Lazzarini,Roger C. Duvoisin,Giuseppe Di Iorio,Lawrence I. Golbe,Robert L. Nussbaum +19 more
TL;DR: A mutation was identified in the α-synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, in the Italian kindred and in three unrelated families of Greek origin with autosomal dominant inheritance for the PD phenotype.
Journal ArticleDOI
Frontotemporal lobar degeneration A consensus on clinical diagnostic criteria
David Neary,Julie S. Snowden,L. Gustafson,U. Passant,Donald T. Stuss,Sandra E. Black,Morris Freedman,Andrew Kertesz,Philippe Robert,Marilyn S. Albert,Kyle B. Boone,Bruce L. Miller,Jeffrey L. Cummings,D. F. Benson +13 more
TL;DR: Consensus criteria for the three prototypic syndromes-frontotemporal dementia, progressive nonfluent aphasia, and semantic dementia-were developed by members of an international workshop on frontotem temporal lobar degeneration and ought to provide the foundation for research work into the neuropsychology, neuropathology, genetics, molecular biology, and epidemiology of these important clinical disorders.
Journal ArticleDOI
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.
Katya Rascovsky,John R. Hodges,David S. Knopman,Mario F. Mendez,Joel H. Kramer,John Neuhaus,John C. van Swieten,Harro Seelaar,Elise G.P. Dopper,Chiadi U. Onyike,Argye E. Hillis,Keith A. Josephs,Bradley F. Boeve,Andrew Kertesz,William W. Seeley,Katherine P. Rankin,Julene K. Johnson,Maria Luisa Gorno-Tempini,Howard J. Rosen,Caroline E. Prioleau-Latham,Albert Lee,Christopher M. Kipps,Christopher M. Kipps,Patricia Lillo,Olivier Piguet,Jonathan D. Rohrer,Martin N. Rossor,Jason D. Warren,Nick C. Fox,Douglas Galasko,David P. Salmon,Sandra E. Black,M.-Marsel Mesulam,Sandra Weintraub,Brad C. Dickerson,Janine Diehl-Schmid,Florence Pasquier,Vincent Deramecourt,Florence Lebert,Yolande A.L. Pijnenburg,Tiffany W. Chow,Facundo Manes,Jordan Grafman,Stefano F. Cappa,Morris Freedman,Murray Grossman,Bruce L. Miller +46 more
TL;DR: The revised criteria for behavioural variant frontotemporal dementia improve diagnostic accuracy compared with previously established criteria in a sample with known frontotmporal lobar degeneration and reflect the optimized diagnostic features, less restrictive exclusion features and a flexible structure that accommodates different initial clinical presentations.
Journal ArticleDOI
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Bradley T. Hyman,Creighton H. Phelps,Thomas G. Beach,Eileen H. Bigio,Nigel J. Cairns,Maria C. Carrillo,Dennis W. Dickson,Charles Duyckaerts,Matthew P. Frosch,Eliezer Masliah,Suzanne S. Mirra,Peter T. Nelson,Julie A. Schneider,Dietmar Rudolf Thal,Bill Thies,John Q. Trojanowski,Harry V. Vinters,Thomas J. Montine +17 more
TL;DR: The new guidelines recognize the pre‐clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, and establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP‐43 inclusions.